What are the Historical Developments and Current Growth Metrics of the Overactive Bladder Treatment Market?
The overactive bladder treatment market has seen considerable growth due to a variety of factors.
• The market size for treating overactive bladder has experienced consistent growth over the past few years. The market is anticipated to increment from $3.15 billion in 2024 to $3.25 billion in 2025, with a compound annual growth rate (CAGR) of 3.3%. The factors contributing to the growth during the historic period include medication development, increased patient awareness, demographic changes, clinical guidelines, and investment in research.
What Is The Projected Growth Of The Overactive Bladder Treatment Market in the Coming Years?
The Overactive Bladder Treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for overactive bladder treatment is anticipated to witness significant expansion. It is predicted to rise to $3.99 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 5.2%.
The surge during the forecast period can be attributed to factors such as the aging population, advancements in therapies, personalized medicine, investments in healthcare, and focus on patient-oriented care. Noteworthy trends predicted for the forecast period consist of non-pharmacological processes, the adoption of digital health solutions, acceptance of alternative medicine, gender-tailored approaches, and comprehensive care.
What Are The Key Drivers Fueling Growth In The Overactive Bladder Treatment Market?
The anticipated growth of the overactive bladder treatment market is largely attributed to an increasing geriatric population. This term pertains to individuals who are 65 years old and above. The susceptibility of geriatric patients to urinary tract infections is higher due to multiple factors like reduced urine flow, overactive bladder, enlarged prostate or presence of kidney stones, thereby escalating the need for overactive bladder treatments. As an illustration, data from ReliefWeb, a humanitarian information platform based in the US, indicated that the global demographic of individuals aged 65 and above is projected to rise from 10% in 2022 to 16% in 2050. Moreover, this population segment is forecasted to increase to 94 million by 2050, making up 23% of the total population. Consequently, the overactive bladder treatment market is gaining momentum due to this surge in the geriatric population.
What Are The Principal Market Segments In The Global Overactive Bladder Treatment Industry?
The overactive bladder treatment market covered in this report is segmented –
1) By Diseases Type: Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity
2) By Therapy: Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Other Therapies
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Idiopathic Bladder Overactivity: Urge Incontinence, Urgency Frequency
2) By Neurogenic Bladder Overactivity: Spinal Cord Injury-Related Overactivity, Multiple Sclerosis-Related Overactivity, Stroke-Related Overactivity
Pre-Book The Overactive Bladder Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Overactive Bladder Treatment Industry?
In the overactive bladder treatment market, it's a prevalent trend to secure product approvals. Leading companies in the industry are introducing sophisticated products that make use of cutting-edge technologies in order to maintain their competitive edge. For example, in April 2023, Avation Medical Inc., an American firm that specializes in advanced neuromodulation and digital health, received FDA approval for The Vivally System. This system is a non-invasive, wearable device for bladder control therapy and a corresponding mobile application to help treat patients with urge urinary incontinence and urinary urgency caused by overactive bladder syndrome. This device intricately merges a comfortable garment worn around the ankle with an intelligent controller that provides individualized neuromodulation energy to the tibial nerve.
Who Are the Key Players In The Overactive Bladder Treatment Market?
Major companies operating in the overactive bladder treatment market include:
• AbbVie Inc.
• Astellas Pharma Inc.
• Laborie Medical Technologies Corporation
• Endo International plc
• Hisamitsu Pharmaceutical Co. Inc.
• Johnson & Johnson Services Inc.
• Medtronic plc
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Limited
• Cogentix Medical Inc.
• Dr. Reddy’s Laboratories Ltd.
• Sumitomo Pharma Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Limited
• Merck & Co. Inc.
• Macleods Pharmaceuticals Ltd.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• GlaxoSmithKline plc
• Janssen Pharmaceuticals Inc.
• Novartis International AG
• Daiichi Sankyo Company ltd.
• Boston Scientific Corporation
• Grünenthal GmbH
• Collegium Pharmaceutical Inc.
What Are The Regional Insights Into The Overactive Bladder Treatment Market?
North America was the largest region in the overactive bladder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the overactive bladder treatment market report during the forecast period. The regions covered in the overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
